B

    Biocardia Inc (BCDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.14
    -0.01 (-0.87%)

    Market Cap: $17.41M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(19/28)
    Avg Surprise
    -14.03%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.15
    Range$-0.15 - $-0.15
    1 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.17-13.3%
    60d ago$-0.18-20.0%
    30d ago$-0.18-20.0%
    7d ago$-0.18-20.0%
    Current$-0.15
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    1 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.20---
    Sep 26EST
    		-$-0.15---
    Jun 26
    		$-0.13$-0.19+31.58%Beat+67.5%
    Mar 26
    		$-0.21$-0.17-23.53%Miss+64.4%
    Dec 25
    		$-0.06N/A+70.00%Beat+76.0%
    Sep 25
    		$-0.24$-0.25+4.00%Beat+60.7%
    Jun 25
    		$-0.40$-0.50+20.00%Beat+54.5%
    Mar 25
    		$-0.59$-0.39-51.28%Miss-554.1%
    Dec 24
    		$-0.25N/A+71.26%Beat+81.5%
    Sep 24
    		$-0.61$-1.19+48.74%Beat+66.1%
    Jun 24
    		$-0.88$-0.10-780.00%Miss+65.5%
    Mar 24
    		$-0.09N/A+54.90%Beat+96.5%
    Dec 23
    		$-1.35$-1.50+10.00%Beat-743.8%
    Sep 23
    		$-1.80$-1.65-9.09%Miss+29.4%
    Jun 23
    		$-2.55$-2.55+0.00%Beat-21.4%
    Mar 23
    		$-2.55$-1.95-30.77%Miss+10.5%
    Dec 22
    		$-0.16$-0.18+11.11%Beat+20.0%
    Sep 22
    		$-2.55$-3.15+19.05%Beat-6.2%
    Jun 22
    		$-2.10N/A+66.67%Beat+30.0%
    Mar 22
    		$-2.85$-2.40-18.75%Miss-1483.3%
    Dec 21
    		$-0.20$-0.21+4.76%Beat+93.4%
    Sep 21
    		$-2.40$-4.20+42.86%Beat+46.7%
    Jun 21
    		$-3.00$-3.45+13.04%Beat+56.5%
    Mar 21
    		$-0.18$-0.24+25.00%Beat+97.5%
    Dec 20
    		$-3.05$-4.65+34.41%Beat-535.4%
    Sep 20
    		$-4.50$-4.35-3.45%Miss+52.4%
    Jun 20
    		$-6.90$-6.00-15.00%Miss-796.1%
    Mar 20
    		$-7.20$-8.40+14.29%Beat-747.1%
    Dec 19
    		$-0.48$-0.51+5.88%Beat+43.3%
    Sep 19
    		$-9.45$-8.70-8.62%Miss-1066.7%
    Jun 19
    		$-0.77N/AN/ABeat-6.9%
    Mar 19
    		$-0.85N/AN/ABeat+88.8%
    Dec 18
    		$-0.85N/AN/ABeat-4.5%
    Sep 18
    		$-0.81N/AN/ABeat-12.5%
    Jun 18
    		$-0.72N/AN/ABeat+93.1%
    Mar 18
    		$-7.59N/AN/ABeat+25.4%
    Dec 17
    		$-0.81N/AN/ABeat-102.3%
    Sep 17
    		$-0.72N/AN/ABeat-
    Jun 17
    		$-10.42N/AN/ABeat-
    Mar 17
    		$-10.18N/AN/ABeat-
    Sep 16
    		$35.99N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.78EV/EBITDA-3.16x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-1803.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio2.09xQuick Ratio2.09x
    Trading Statistics
    Beta0.49Avg Volume260.72K
    52-Week High$2.2952-Week Low$0.75

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.08
    SMA 20$1.01
    SMA 50$0.98
    SMA 200$1.14
    EMA 10$1.09
    EMA 20$1.03
    EMA 50$0.99
    EMA 200$1.17

    MACD

    Line: 0.06Signal: 0.04Hist: 0.02

    ADX

    ADX: 22.6+DI: 26.4-DI: 14.4

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down4.0
    PSAR$1.05

    Bollinger Bands

    Upper Band$1.20
    Lower Band$0.82
    %B Position3754%(Upper)
    Band Width0.84

    RSI (14-Day)

    Neutral
    64.2

    Momentum Oscillators

    Stoch %K79.7
    Stoch %D85.7
    Williams %R-23.8
    ROC (10d)21.3%
    Momentum0.20
    CCI (20d)115.2
    MFI (14d)72.4

    Volatility Measures

    ATR (14d)$0.08(7.0%)
    StdDev (20d)0.09
    Hist Vol65.1%(High)

    Volume Flow

    VWAP$1.13
    OBV130.5M
    AD Line-123.8M
    CMF (20d)0.269

    Volume Metrics

    Avg Vol (20d)269.0K
    Vol Ratio0.5x
    VWMA (20d)$1.00

    Pivot Points

    R3$1.28
    R2$1.24
    R1$1.19
    Pivot Point$1.15
    S1$1.11
    S2$1.07
    S3$1.02

    Advanced Oscillators

    TSI24.01
    Ultimate Osc68.3
    KST178.49

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$-55,000$0$0$55,000$13,000$357,000
    Cost of Revenue$0$0$185,000$0$0$0$1.42M$0$0$0$1.16M$0
    Gross Profit$0$0$-185,000$0$0$0$-55,000$0$0$55,000$13,000$357,000
    Operating Expenses$1.62M$2.27M$2.01M$1.49M$2.05M$2.73M$2.32M$1.76M$1.65M$2.33M$2.10M$2.96M
    R&D$893,000$1.24M$1.13M$936,000$1.37M$1.53M$1.42M$931,000$800,000$1.24M$1.16M$1.87M
    SG&A$730,000$1.03M$885,000$552,000$683,000$1.20M$906,000$825,000$852,000$1.09M$941,000$1.08M
    Operating Income$-1,623,000$-2,266,000$-2,013,000$-1,488,000$-2,051,000$-2,726,000$-2,321,000$-1,756,000$-1,649,000$-2,275,000$-2,084,000$-2,598,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$28,000$0
    Income Before Tax$-1,613,000$-2,259,000$-1,984,000$-1,483,000$-2,049,000$-2,712,000$-2,288,000$-1,737,000$-1,646,000$-2,275,000$-2,112,000$-2,598,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-1,613,000$-2,259,000$-1,984,000$-1,483,000$-2,049,000$-2,712,000$-2,296,000$-1,737,000$-1,646,000$-2,267,000$-2,072,000$-2,574,000
    EBITDA$-1,499,000$-2,142,000$-1,828,000$-1,381,000$-1,928,000$-2,593,000$-2,092,000$-1,648,000$-1,543,000$-2,169,000$-2,064,000$-2,577,000
    EBIT$-1,623,000$-2,266,000$-2,013,000$-1,488,000$-2,051,000$-2,726,000$-2,321,000$-1,756,000$-1,649,000$-2,275,000$-2,084,000$-2,598,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCDA

    News

    BioCardia plans an FDA review step for its heart-delivery catheter

    BioCardia (Nasdaq: BCDA) announced that the FDA has finalized the May 2026 Pre-Submission Meeting minutes for its Helix Transendocardial Delivery Catheter System, confirming the company's understanding of regulatory feedback. BioCardia plans to submit a follow-on pre-submission this quarter, incorporating FDA advice, which could lead to Helix approval via the De Novo pathway. The company believes this market clearance would enhance development and commercial partnering for high-value therapeutic agents.

    Stock Titan•8/24/26•
    Bullish

    BioCardia says FDA ratifies Helix meeting minutes, paving way for De Novo pre-submission

    BioCardia announced that the FDA has accepted the meeting minutes from their May 2026 meeting regarding the Helix catheter, making them final. This ratification paves the way for BioCardia to submit a follow-on De Novo pre-submission for the Helix catheter this quarter, incorporating the FDA's advice. Successful De Novo approval would allow independent market clearance and support further development and partnering for the Helix system, a minimally invasive platform for targeted intramyocardial delivery.

    TradingView•8/24/26•
    Bullish

    BioCardia Received Notice of Noncompliance

    BioCardia (BCDA) received a notice from Nasdaq stating that its common stock failed to meet the minimum bid price requirement of $1.00 for 30 consecutive business days. The company has 180 days, until February 16, 2027, to regain compliance, with a possibility of an additional 180-day extension. This notice does not immediately affect the trading of its stock.

    TradingView•8/21/26•
    Bearish

    BioCardia’s Q2 2026 Update Keeps the Regulatory Story Alive, but Capital Still Drives the Risk

    BioCardia's Q2 2026 update highlighted significant regulatory progress for its CardiAMP and Helix programs in both Japan and the U.S., reinforcing its identity as a development-stage company. Despite narrowing losses and efficient capital use, the company remains cash-constrained, with liquidity being a primary valuation variable. Future success hinges on converting regulatory milestones into approvals or partnerships quickly enough to alleviate ongoing financing pressures.

    AlphaStreet•8/20/26•
    Neutral

    BioCardia CEO Peter Altman buys $5,022 in company stock

    BioCardia's CEO, Peter Altman, recently purchased 5,400 shares of company stock for a total of $5,022, increasing his direct holdings to 381,115 shares. This comes as the stock trades near its 52-week low, with InvestingPro analysis suggesting it is undervalued. The company also reported a smaller-than-expected loss for Q2 2026 and positive regulatory progress for its CardiAMP cell therapy in Japan and the U.S.

    Investing.com•8/19/26•
    Bullish

    Frequently Asked Questions About BCDA

    Does BCDA pay dividends?
    Biocardia Inc (BCDA) does not currently pay a regular dividend.
    What is BCDA's market cap?
    Biocardia Inc (BCDA) has a market capitalization of $17.41M with a current stock price of $1.14.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In